Last reviewed · How we verify

NCT07163806

Volumetric Parameter of 18F-FDG PET/CT in Characterizing Thyroid Incidentalomas

Not yet recruiting Last updated 29 September 2025
What this trial tests

trial testing PET/CT with 18-FDG in Thyroid Incidentalomas in 88 participants. Not yet recruiting.

Timeline
30 October 2025
Primary endpoint
30 April 2028
30 May 2028

Quick facts

Lead sponsorFatma Abelzaher Mahmoud Ahmed
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment88
Start date30 October 2025
Primary completion30 April 2028
Estimated completion30 May 2028

Drugs / interventions tested

Conditions studied

Sponsor

Fatma Abelzaher Mahmoud Ahmed

Who can join

Adults 18 to 90, any sex, with Thyroid Incidentalomas. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the clinical significance of FDG-avid thyroid incidentalomas detected on PET/CT and explore correlations between SUV max, ultrasound characteristics, and histopathology for suspicious lesion.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of PET/CT with 18-FDG

Trials testing the same drug.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07163806.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing